Sign in
Taking people in United StatesPhase 2

Daratumumab Added to Transplant for Sickle Cell Disease With Donor Antibodies

Tests daratumumab before transplant in young people with sickle cell disease and donor antibodies.

Key facts

Who runs it
Children's National Research Institute
Where
Washington D.C., United StatesSee the site
Trial code
Registry title
Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody
Status
Recruiting
Phase
Phase 2
People taking part
12 people, planned
Started
3 Apr 2024
Expected to end
Sept 2054
Type of study
Interventional, 2 groups
Treatments tested
  • Daratumumab
  • Alemtuzumab
  • Sirolimus
  • Total Body Irradiation
Record updated
26 September 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young people with sickle cell disease who have a healthy brother or sister as a tissue-compatible donor and who have antibodies against the donor's red blood cells, or whose donor has a major blood group difference.

Age
2 to 24.99 years (listed as 2 to 25 years)
Sex
All sexes can join.
Disease stage
Sickle cell disease with a serious complication, such as stroke, repeated acute chest syndrome, repeated pain events needing opiate or IV pain medicine, hospital stays for the disease, priapism, regular red cell transfusions or spleen sequestration.
Earlier treatment
Some people need regular red blood cell transfusions (8 or more in the previous 12 months). Others need hospital care for pain or acute chest syndrome while taking hydroxyurea.
Biomarker or test result
A healthy HLA-identical sibling donor with a major ABO blood group difference, or the patient has red blood cell antibodies against other donor red cell antigens.

Main reasons for not taking part

  • Life expectancy less than 6 month
  • Pregnant or breastfeeding
  • HIV-positive, or active or past hepatitis B or C
  • Uncontrolled infection within 1 month before conditioning
  • Serious liver, heart, kidney or lung problems or uncontrolled asthma

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • General:
  • Patients with SCD age 2-24.99 years who have a healthy HLA-identical sibling donor with major ABO incompatibility OR patients with RBC alloantibodies against other donor RBC antigens
  • Patients must have an absolute neutrophil count of 1 x 109/L and a platelet count of 100 x 109/L
  • Lansky/Karnofsky score of, at least, 70; Patients with genotypes hemoglobin SS and Sβ0 thalassemia must have at least one of the following:
  • History of an abnormal transcranial Doppler measurement defined as TCD velocity ≥200 cm/sec by the non-imaging technique measured at a minimum of two separate occasions
  • Progression of CNS vasculopathy on MRA determined to be secondary to SCD
  • History of cerebral infarction on brain MRI (overt stroke, or silent stroke if ≥3 mm in one dimension, visible in two planes on fluid-attenuated inversion recovery T2-weighted images)
  • History of two or more episodes of Acute Chest Syndrome (ACS) in lifetime
  • History of three or more SCD pain events requiring treatment with an opiate or IV pain medication in lifetime
  • History of any hospitalization for a complication secondary to SCD (does NOT include empiric hospitalizations for fever only)
  • History of two or more episodes of priapism
  • Administration of regular RBC transfusions (≥8 transfusions episodes in the previous 12 months)
  • At least two episodes of splenic sequestration requiring red blood cell transfusion or splenectomy after at least one episode of splenic sequestration; Patients with all other sickle genotypes (e.g. hemoglobin SC, Sβ+ thalassemia, etc.) must have at least one of the following:
  • Clinically significant neurologic event (overt stroke)
  • History of two or more episodes of ACS in the 2-year period preceding enrollment
  • History of three or more SCD pain events requiring treatment with an opiate or IV pain medication (inpatient or outpatient) in the 1-year period preceding enrollment
  • History of any hospitalization for SCD pain or ACS while receiving hydroxyurea treatment
  • History of two or more episodes of priapism (erection lasting ≥4 hours or requiring emergent medical care)
  • Administration of regular RBC transfusions (≥8 transfusions in the previous 12 months)
  • At least two episodes of splenic sequestration requiring red blood cell transfusion or splenectomy after at least one episode of splenic sequestration

Who cannot take part

  • Infectious Disease: Uncontrolled bacterial, viral or fungal infections (undergoing appropriate treatment and with progression of clinical symptoms) within 1 month prior to conditioning. Patients with febrile illness or suspected minor infection should await clinical resolution prior to starting conditioning. Patients with confirmed seropositivity for HIV and patients with active or resolved Hepatitis B or C determined by serology and/or NAAT are excluded
  • Liver: Direct (conjugated) bilirubin > 1.5 mg/dL. Transaminases >5x upper limit of normal for age
  • Cardiac: Left ventricular shortening fraction <25% or ejection fraction <50% by ECHO. Uncontrolled cardiac arrhythmia
  • Kidney: Estimated creatinine clearance less than 60 mL/min/1.73m2
  • Pulmonary function: Diffusion capacity of carbon monoxide (DLCO) <35% (adjusted for hemoglobin). Baseline oxygen saturation <94% at rest or PaO2 <70. Known moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification
  • Life expectancy less than 6 month
  • Pregnant or breastfeeding patients
  • Heme: Available, medically suitable, and equivalent HLA-matched sibling donor, who does not have major ABO incompatibility or express RBC antigens against which the patient is alloimmunized

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 2 and 25 years old?

Where in United States

  • Children's National HospitalWashington D.C., United StatesContact: Maryanne OdinakachukwuTaking people

About the trial

What the trial wants to find out

This multicenter prospective study seeks to determine if daratumumab given, prior to HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus, can prevent pure red blood cell aplasia with an acceptable safety profile in patients with anti-donor red blood cell antibodies, achieving an event-free survival similar to transplanted patients without such antibodies.

The 2 groups in the trial

  • Recipients with a major ABO incompatible donorTreatment being tested

    Patients in this cohort are treated pre-HCT with Daratumumab, intravenously, on days -49, -42, -35 and -28. The conditioning regimen will consist of alemtuzumab, given subcutaneously, daily for 5 days (days -7 to -3) and low dose total body irradiation (TBI) 300 cGY on day -2 with gonadal shielding. Sirolimus will be given as GVHD prophylaxis for the first year with weaning thereafter based on donor T-cell chimerism. G-CSF, at 5 mcg/kg/day, will be given post stem cell infusion until neutrophil engraftment is achieved.

    Treatment: Daratumumab, Alemtuzumab, Sirolimus, and Total Body Irradiation

  • Recipients with red cell alloantibodies (non-ABO) against donor antigensTreatment being tested

    Patients in this cohort are treated pre-HCT with Daratumumab, intravenously, on days -49, -42, -35 and -28. The conditioning regimen will consist of alemtuzumab, given subcutaneously, daily for 5 days (days -7 to -3) and low dose total body irradiation (TBI) 300 cGY on day -2 with gonadal shielding. Sirolimus will be given as GVHD prophylaxis for the first year with weaning thereafter based on donor T-cell chimerism. G-CSF, at 5 mcg/kg/day, will be given post stem cell infusion until neutrophil engraftment is achieved.

    Treatment: Daratumumab, Alemtuzumab, Sirolimus, and Total Body Irradiation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Sickle Cell Disease Transplant Using a Nonmyeloablative Approach: Adding Daratumumab for Patients With Anti-donor Red Cell AntibodY
Plain-language title
Daratumumab Added to Transplant for Sickle Cell Disease With Donor AntibodiesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06358638, who can take part
Record updated
26 September 2025